JAK1 Inhibition with Upadacitinib in a Patient with Refractory Severe Chronic Spontaneous Urticaria and Concomitant Rheumatoid Arthritis: Complete Resolution of Urticaria and Remission of Rheumatoid Arthritis
DOI:
https://doi.org/10.2340/actadv.v105.44312Keywords:
urticaria, urticaria activity score, refractory, omalizumab, JAK inhibitors, JAK kinase inhibitor, UpadacitinibDownloads
References
Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022; 77: 734–766. DOI: https://doi.org/10.1111/all.15090
Kolkhir P, Fok JS, Kocatürk E, Li PH, Okas TL, Marcelino J, et al. Update on the treatment of chronic spontaneous urticaria. Drugs 2025; 85: 475–486. DOI: https://doi.org/10.1007/s40265-025-02170-4
Kaplan A, Lebwohl M, Giménez-Arnau AM, Hide M, Armstrong AW, Maurer M. Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances. Allergy 2023; 78: 389–401. DOI: https://doi.org/10.1111/all.15603
Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 2022; 18: 133–145. DOI: https://doi.org/10.1038/s41584-021-00726-8
Mohamed MF, Bhatnagar S, Parmentier JM, Nakasato P, Wung P. Upadacitinib: mechanism of action, clinical, and translational science. Clin Transl Sci 2024; 17: e13688. DOI: https://doi.org/10.1111/cts.13688
Zhang TY, Zeng YP. Off-label use of JAK1 inhibitor upadacitinib in dermatology. Arch Dermatol Res 2025; 317: 363. DOI: https://doi.org/10.1007/s00403-025-03890-z
Wong D, Waserman S, Sussman GL. Endotypes of chronic spontaneous urticaria and angioedema. J Allergy Clin Immunol 2025; 156: 17–23. DOI: https://doi.org/10.1016/j.jaci.2025.04.004
Fukunaga A, Ito M, Nishigori C. Efficacy of oral ruxolitinib in a patient with refractory chronic spontaneous urticaria. Acta Derm Venereol 2018; 98: 904–905. DOI: https://doi.org/10.2340/00015555-3006
Mansouri P, Mozafari N, Chalangari R, Martits-Chalangari K. Efficacy of oral tofacitinib in refractory chronic spontaneous urticaria and urticarial vasculitis. Dermatol Ther 2022; 35: e15932. DOI: https://doi.org/10.1111/dth.15932
Weaver M, Gierer S, Badawi A. A case of comorbid alopecia universalis and chronic spontaneous urticaria treated with baricitinib. Ann Allergy Asthma Immunol 2024; 133: S134. DOI: https://doi.org/10.1016/j.anai.2024.08.553
ClinicalTrials.gov. Study of povorcitinib (INCB54707) in participants with chronic spontaneous urticaria. NCT05936567. Available from: https://clinicaltrials.gov/study/NCT05936567
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Israel Magen, Iris Leibovich, Eli Magen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
